Edition:
India

Beyondspring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

17.16USD
1:30am IST
Change (% chg)

$-0.06 (-0.35%)
Prev Close
$17.22
Open
$17.20
Day's High
$17.52
Day's Low
$16.93
Volume
6,537
Avg. Vol
26,460
52-wk High
$25.79
52-wk Low
$13.18

Latest Key Developments (Source: Significant Developments)

BeyondSpring Provides Operational Update, Q1 Financial Results
Wednesday, 10 Jul 2019 

July 10 (Reuters) - BeyondSpring Inc ::BEYONDSPRING PROVIDES OPERATIONAL UPDATE AND FIRST QUARTER 2019 FINANCIAL RESULTS.BEYONDSPRING INC - TO SUBMIT NDAS IN U.S. FOR BOTH NSCLC AND CIN IN 2020.BEYONDSPRING - TO SUBMIT NDAS IN CHINA FOR BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN) IN Q4 2019 / Q1 2020.BEYONDSPRING INC - NET LOSS PER SHARE FOR QUARTER ENDED MARCH 31, 2019 $0.32.BEYONDSPRING INC - AT MARCH 31, 2019, BEYONDSPRING HAD $1.96 MILLION IN CASH.  Full Article

BeyondSpring Announces Top Line Positive Efficacy From Phase 2 Study 106
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - BeyondSpring Inc ::BEYONDSPRING ANNOUNCES TOP LINE POSITIVE EFFICACY AND SAFETY DATA FROM PHASE 2 STUDY 106 WITH LEAD ASSET, PLINABULIN, FOR CHEMOTHERAPY-INDUCED NEUTROPENIA PREVENTION.BEYONDSPRING INC - ON TRACK FOR OUR PLANNED SUBMISSION OF A NEW DRUG APPLICATION (NDA) FOR TREATMENT OF CIN IN CHINA IN LATE 2018 OR EARLY 2019.BEYONDSPRING INC - ON TRACK FOR PLANNED SUBMISSION OF A NEW DRUG APPLICATION (NDA) FOR TREATMENT OF CIN IN U.S. IN SECOND HALF OF 2019.BEYONDSPRING INC - PHASE 2 DATA FROM STUDY 106 DEMONSTRATED STATISTICALLY SIGNIFICANT EFFICACY OF PLINABULIN/NEULASTA COMBO.  Full Article

BeyondSpring Reports Quarterly Loss Per Share $0.54
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - BeyondSpring Inc ::BEYONDSPRING PROVIDES OPERATIONAL UPDATE AND SECOND-QUARTER 2018 FINANCIAL RESULTS.BEYONDSPRING - REPORTED TOP LINE POSITIVE EFFICACY AND SAFETY DATA FROM PHASE 2 STUDY 106 EVALUATING PLINABULIN IN COMBINATION WITH NEULASTA FOR CIN PREVENTION.BEYONDSPRING INC - ON TRACK TO REPORT INTERIM DATA FROM PHASE 3 STUDY 105 IN 4Q 2018.BEYONDSPRING INC QUARTERLY LOSS PER SHARE $0.54.BEYONDSPRING INC - ON TRACK TO SUBMIT NDA TO CHINA FOOD AND DRUG ADMINISTRATION (CFDA) FOR CIN IN LATE 2018 / EARLY 2019.BEYONDSPRING - ON TRACK TO REPORT INTERIM DATA FROM PHASE 3 STUDY 103 IN EARLY 2019, SUBMIT NDA TO CFDA FOR NON-SMALL CELL LUNG CANCER IN H1 2019.  Full Article

BeyondSpring Reports Quarterly Loss Per Share Of $0.61
Thursday, 21 Jun 2018 

June 21 (Reuters) - BeyondSpring Inc ::BEYONDSPRING PROVIDES OPERATIONAL UPDATES AND FIRST-QUARTER 2018 FINANCIAL RESULTS.BEYONDSPRING INC - QTRLY LOSS PER SHARE $0.61.BEYONDSPRING INC - CASH AND SHORT-TERM INVESTMENTS WERE $21.5 MILLION AT MARCH 31, 2018, COMPARED TO $30.6 MILLION AT DECEMBER 31, 2017.  Full Article

BeyondSpring Says May Offer And Sell Up To 5 Mln Of Co's Ordinary Share From Time to Time
Thursday, 26 Apr 2018 

April 25 (Reuters) - BeyondSpring Inc ::BEYONDSPRING INC SAYS MAY FROM TIME TO TIME OFFER AND SELL, IN ONE OR MORE OFFERINGS, UP TO 5 MILLION OF CO'S ORDINARY SHARE - SEC FILING.  Full Article

Beyondspring Says, Co Appointed Edward Dongheng Liu As Its Chief Financial Officer, Effective Immediately
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Beyondspring Inc ::BEYONDSPRING SAYS ON MARCH 26, CO APPOINTED EDWARD DONGHENG LIU AS ITS CHIEF FINANCIAL OFFICER, EFFECTIVE IMMEDIATELY - SEC FILING.  Full Article

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Beyondspring Inc ::BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN).BEYONDSPRING INC - INTERIM ANTI-CANCER EFFICACY DATA FROM PHASE 3 NSCLC CLINICAL TRIAL IS EXPECTED IN MID-2018.  Full Article

Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Beyondspring Inc ::BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY.BEYONDSPRING INC - ‍EXPECT CFDA FILINGS OF FIRST NDAS FOR BOTH CIN AND NSCLC INDICATIONS POTENTIALLY IN 2018​.  Full Article

BeyondSpring qtrly loss per share $‍0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - BeyondSpring Inc :BeyondSpring reports third quarter 2017 operational and financial results.BeyondSpring Inc - qtrly loss per share $‍0.68​.  Full Article